32nd ESH Scientific Meeting – Hypertension & Cardiovascular Protection

The Meeting will devote its attention primarly to the mechanistic, diagnostic and therapeutic novelties that have been obtained on hypertension in the recent past. It will also focus, however, on the comorbidities that are closely related to the high blood pressure condition, including risk factors such as diabetes mellitus, dyslipidemias and obesity as well as coronary artery heart disease, stroke, heart failure, peripheral artery abnormalities and dementia. Our aim is to develop a Meeting that provides a critical update on research progress in this fundamental area of medicine and in the mean time helps clinical practice to obtain optimal management of the hypertensive patient. In this context a key aspect of the meeting will be the presentation of the new ESH hypertension guidelines which will then be widely discussed by the audience and among experts.

The scientific programme will consist of multiple State-of-the-Art Lectures, Debates and Round Tables, and Live Cases on issues of major current clinical interest, targeting enhanced interaction with both digital and physical audience. The Meeting will be an integrated scaffold of learning, sharing knowledge and breakthrough science. Drawing on past meetings, the program will include, How-to, Meet the Expert and Clinical case sessions, as well as special sessions reserved to hypertension specialists and ESH Excellence Centres.

As usually, the ESH meeting will be held in the Congress Center of the Milan City Fair, which can optimally accommodate the large number of participants and the diversified scientific and educational activities that characterize the European Hypertension Meetings, with also a suitable exhibition space for the Industry. The City Fair is only few stops away from the center of Milan (the Cathedral Square) and can be easily reached from major Hotels.

Your participation will contribute significantly to the success of the Meeting!

We are looking forward to welcoming you in Milan!

Data protection information sheet for participants to events

AIM Italy S.r.l. (hence, the “Controller” or “AIM”), in its quality of Data Processing Controller, as per section 13 of the EU Regulation n. 679/2016 (hence, the “Data Protection Regulation”), and subsequent modifications and integrations, collects and subsequently processes personal data1 of the participants (hence, the ’“Data Subject”) – including as teachers or learner – to the congress and/or other scientific or training event (hence, the ’“Event”), also held remotely.

Scopes and ways of processing

The personal data of Data Subjects are processed in the context of AIM’s commercial activity, for the following scopes:

• subscription and participation to the Event;
• fiscal, administrative and accounting duties strictly connected to above participation;
• execution of specific duties prescribed by law, regulation or EU norms (such as administration of credits for Continuing Medical Education);
• distribution free of charge of documentation relating to the Event;
• use of the Data Subject image, sent/uploaded by the same, due to publish it on the digital platform of the Event (if any);
• receipt of documentation from AIM in order to be updated on all its projects, initiatives and events, both my means of automated tools (such as newsletters, e-mails, SMS, MMS, robocalls, ) and by means of traditional tools (hardcopy mail and/or operator calls) in the same area of interest.

The processing of the personal data is executed, under authority of the Controller, by entities specifically Designated, authorized and instructed for the processing as per section 2-quaterdecies of Italian Law Decree n. 196 dated June 30, 2003, as amended by Italian Law Decree n. 101 dated August 10, 2018 (hence, the “Privacy Law”) and as per sections 29 of the Data Protection Regulation, by means of manual, automated or telecom tools, with logics strictly connected to the scopes and in any case in such a way as to guarantee confidentiality and security of the personal data.

Juridical basis for processing, nature of transfer and consequences of denial, consent by Data Subject.

With reference to the scopes listed at preceding section 1, items 1., 2., 3., 4.,5. and 6, transfer of the personal data is mandatory and represents a necessary condition to the subscription and subsequent participation to the Event and receipt of documentation from AIM about future projects, initiatives and events in the same area of interest; indeed, failure to transfer will determine impossibility of subscribing the Data Subject to the Event and of involving him/her in any initiative of the Event or other AIM’s future projects, initiatives and events of the same area of interest; thus, the juridical base of the related processing is the full participation to the Event and the next update on AIM’s future projects, initiatives and events of the same area of interest, as per section 6, paragraph 1, letter b of the Data Protection Regulation.

Topics

• ageing;
• atrial fibrillation and heart failure;
• big data, precision medicine, artificial intelligence, machine learning;
• biomarkers;
• blood pressure measurement;
• blood pressure treatment thresholds and targets;
• blood pressure variability;
• cardiovascular oncology;
• cardiovascular risk factors;
• cerebrovascular diseases, cognitive dysfunction and dementia;
• children and adolescents;
• co-morbidities in hypertension;
• coronary heart disease;
• covid-19 and cardiovascular disease;
• covid-19 and hypertension;
• diabetes;
• endocrine hypertension;
• endothelium and atherosclerosis;
• epidemiology of hypertension and metabolic disorders;
• ethnic aspects;
• experimental hypertension and pharmacology;
• genetics, genomics, proteomics, metabolomics;
• global burden of hypertension economical aspects;
• global cvd prevention;
• heart and haemodynamics;
• high altitude;
• home bp ambulatory;
• imaging in hypertension;
• inflammation and immunity;
• interventional therapy and devices;
• kidney;
• large arteries;
• lifestyle changes salt diets lipids;
• microcirculation/small vessels;
• nocturnal blood pressure;
• obesity, sleep apnoea and metabolic syndrome;
• pregnancy;
• primary care/family medicine;
• renin-angiotensin-aldosterone system;
• resistant hypertension;
• sport and exercise;
• stroke;
• sympathetic nervous system and other neural mechanisms;
• therapeutics and clinical trials;
• treatment adherence and inertia threshhold and target in hypertension.